Merck says study confirms efficacy of Erbitux drug
FRANKFURT (Reuters) - Merck KGaA said on Wednesday a Phase II trial provided further evidence that its cancer drug Erbitux was particularly effective at fighting bowel tumors whose cells did not undergo a certain type of genetic mutation.<div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/healthNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=Q3whnrnS) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=JYPU2ecj" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=JYPU2ecj) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=a2rFo88S" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=a2rFo88S)
</div><img src="http://feedproxy.google.com/~r/reuters/healthNews/~4/GXb8Evx7nsc" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/GXb8Evx7nsc/idUSTRE50D4VT20090114